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OBJECTIVE: To assess the risk factors, incidence and severity of adverse drug reactions in in-patients.
METHODS: This prospective study evaluated 472 patients treated at a teaching hospital in Brazil between 2010
and 2013 by five medical specialties: Internal Medicine, General Surgery, Geriatrics, Neurology, and Clinical
Immunology and Allergy. The following variables were assessed: patient age, gender, comorbidities, family
history of hypersensitivity, personal and family history of atopy, number of prescribed drugs before and during
hospitalization, hospital diagnoses, days of hospitalization. The patients were visited every other day, and
medical records were reviewed by the investigators to detect adverse drug reactions.
RESULTS: There were a total of 94 adverse drug reactions in 75 patients. Most reactions were predictable and of
moderate severity. The incidence of adverse drug reactions was 16.2%, and the incidence varied, according to
the medical specialty; it was higher in Internal Medicine (30%). Antibiotics were the most commonly involved
medication. Chronic renal failure, longer hospital stay, greater number of diagnoses and greater number of
medications upon admission were risk factors. For each medication introduced during hospitalization, there was
a 10% increase in the rate of adverse drug reaction. In the present study, the probability of observing an adverse
drug reaction was 1 in 104 patients per day.
CONCLUSIONS: Adverse drug reactions are frequent and potentially serious and should be better monitored
in patients with chronic renal failure or prolonged hospitalization and especially in those on ’polypharmacy’
regimens. The rational use of medications plays an important role in preventing adverse drug reactions.
KEYWORDS: Adverse Drug Reactions; Hypersensitivity Reactions; In-patients; Incidence; Risk factors.
’ INTRODUCTION
Adverse drug reactions (ADRs) in hospitalized patients
can be divided into two categories: those that are the cause of
hospital admission, and those that occur during hospitaliza-
tion (1). There are limited data on ADRs, especially regarding
the reactions that occur after admission. It is estimated that
ADRs occur in 10% of the general population and 10 to
20% of in-patients (1,2). Approximately 15 to 20% of ADRs
correspond to hypersensitivity drug reactions (HDRs), which
are induced by exposure to a drug in a dose that is usually
tolerated by healthy individuals, and the reactions are
characterized by objective symptoms that can be reproduced
following subsequent re-exposure (2, 3).
A meta-analysis of 33 prospective studies from the United
States, between 1966 and 1996, showed that 15.1% of hos-
pitalized patients suffered an ADR and 0.32% of patients
hospitalized died because of an ADR, with an estimated
106,000 deaths during this period (4). There are questions
about the methodology and validity of this study because of
its heterogeneity, including differences in population, sur-
veillance techniques and ADR definitions (5). In England,
a study evaluating 18,820 patients, has found that 6.5% of
hospitalizations were directly caused by an ADR, and ano-
ther research showed that 15.8% of hospitalized patients
developed an ADR (1, 6).
With the current demographic changes, such as an aging
population, in addition to changes in clinical practice that
have occurred in recent decades, there is a need for further
studies on ADRs (1). The detection of ADRs in hospitals is
an important measure of morbidity associated with drug
use, and their burden on health system (7). The incidence of
hospital ADRs is a key parameter for determining the quality
of care. Furthermore, inadequate information about ADR
rates is the most important factor in the failure to adopt
measures that have a significant impact on patient safety (8).
In-patients represent a population of special interest
because ADRs can be observed directly in these patients,DOI: 10.6061/clinics/2018/e185
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who usually have many comorbidities and require treatment
with special medications (9). The present study assessed the
clinical and demographic features of patients with ADRs,
identifying the risk factors associated with the reactions.
’ METHOD
Study design and subjects
This observational and prospective study was perfor-
med from February 2010 to December 2013 in five medical
specialty infirmaries specialties at the Hospital das Clínicas
da Faculdade de Medicina da Universidade de São Paulo
(HCFMUSP), a tertiary teaching hospital. The medical spe-
cialties involved in the study were: Internal Medicine, Sur-
gery, Neurology, Geriatrics, and Immunology. The study
protocol was approved by the HCFMUSP Ethics Committee
(Protocol: 550/08) and was in accordance with the Helsinki
Declaration of 1975. All patients provided written informed
consent.
A convenience sample was selected to form a prospective
cohort. Sampling occurred on random days and ended when
we recruited the target number of patients (n=100) from each
infirmary.
The follow-up was performed from study inclusion until
hospital discharge. The included were at least 18 years of
age, represented both genders, had a minimum hospital stay
of 48 hours, and had the cognitive ability to answer the study
questionnaires. Patients with an ADR as the cause of hospi-
talization were excluded. If there were repeated hospitaliza-
tions for a single patient, only data from the first admission
were included.
Procedures
Participants were interviewed with the questionnaire sug-
gested by ENDA (European Network for Drug Allergy) (10,11).
A questionnaire assessing asthma and atopy, developed
from GINA (Global Initiative for Asthma) and ISAAC (Inter-
national Study of Asthma and Allergies in Childhood), was also
used (12-14).
All questionnaires were administered by a single resear-
cher, MRR, who is a specialist in clinical immunology and
allergy, with expertise in drug adverse reactions. After the
first interview, visits on alternate days were conducted by
the same researcher to monitor patient records, laboratory
exams, and prescriptions. Patients in each infirmary were
followed until discharge. All patients were instructed to
contact or visit their medical specialty if they had any
reaction within 30 days after hospital discharge. The medical
staff at the medical specialties were oriented about the study
and could directly inform the researchers when there was
an ADR.
Admission to the hospital was considered the exposure
and the presence or absence of ADRs was the outcome. The
definition suggested by the World Health Organization for
an ADR is: ‘‘undesirable and unintended reactions that occur
due to the use of a particular medication at pharmacological
doses for therapy, prophylaxis or diagnosis’’ (15). HDRs,
a subgroup of ADRs, which are based on the individual’s
predisposition, include unexpected reactions initiated by
exposure to a drug, in a dose usually tolerated by healthy
individuals, and characterized by objective signs and symp-
toms that could be reproduced following re-exposure (3). The
scale of probability (Naranjo et al.) was used to establish
a causal relationship and classify the ADRs as ’possible,
probable or definite’ (16). Any ADRs that were classified
as ’doubtful’ were excluded. We classified the ADRs as A
(predictable) and B (unpredictable), according to criteria
developed by Rawlins and Thompson (17). The ADRs were
scored according to severity using the criteria of Hartwig
et al. (i.e., ‘‘mild, moderate or severe’’) (18). All classifications
were made by consensus of three researchers, MRR, AAM,
and PGB.
The following qualitative variables were assessed: gender,
race, age, family history of HDRs, personal and/or family
history of atopy, asthma diagnosis, chronic renal failure,
congestive heart failure, liver disease, human immunodefi-
ciency virus (HIV) infection, and chronic urticaria. The quan-
titative variables that were measured included the number
of comorbidities, number of hospital diagnoses, number of
medications before and during hospitalization, and number
of days of hospitalization. The medical specialties were com-
pared using qualitative and quantitative variables.
Statistical Analysis
Patient characteristics were described using absolute and
relative frequencies for the qualitative variables, and sum-
mary measures (mean, standard deviation, median, P25 and
P75) for the quantitative variables. The associations between
qualitative variables and the medical specialties were checked
using chi-square tests, or tests of likelihood ratio, according
to Kirkwood and Sterne (19). Quantitative characteristics
were compared using the Kruskal-Wallis test, followed by
the Dunn multiple comparison (except for ages, which were
compared using ANOVA, followed by Tukey’s multiple
comparisons) (20).
The chi-square test of likelihood ratio test or the Fisher
exact test was used to identify possible associations between
qualitative variables. Quantitative variables, according to the
occurrence of reactions, were compared using the Mann-
Whitney U-test, except for age, which was compared using
Student’s t-test (19). The odds ratios of each variable of
interest associated with the general ADRs and HDRs, with
confidence intervals of 95%, were calculated using simple
logistic regression, which was performed to quantify the
isolated influence of each feature in the adverse reaction
events (21).
Multiple logistic regression models were estimated for the
general ADRs by selecting the variables that showed levels
of significance lower than 0.20 (po0.20) in the bivariate tests,
and lower than 0.05 (po0.05) for the HDRs because of the
low number of hypersensitivity reactions (21).
’ RESULTS
A total of 472 patients were selected and 8 (1.7%) were
hospitalized due to ADRs. Therefore, the prevalence of ADRs
as a cause of hospitalization was 1.7%. We included 464 patients
distributed as follows: 100 patients each in Geriatrics, Internal
Medicine and General Surgery, and 103 patients in Neurology.
Immunology included only 61 patients, due to a large number
of readmissions.
The average age of the patients included in the study was
57.5 years (SD±19.9), and 239 (51.5%) were female. The
mean hospital stay was 16.8 days, and the average number of
medications used during hospitalization was 15.5 medica-
tions per patient.
We observed 94 ADRs in 75 patients who had at least one
adverse reaction. The overall incidence of ADRs during
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hospitalization was 16.2%, and the incidence of ADRs
according to the medical specialty varied; the incidence
was higher in Internal Medicine (Figure 1) (p=0.001). There
was no difference in the incidence of HDRs between medical
specialties (p=0.278).
There were more ADRs in patients with chronic renal
failure (p=0.012), prolonged hospital stays (po0.001), higher
number of diagnoses (po0.001), and higher number of
medications used during their hospital stay (po0.001). After
multiple logistic regression models were applied, it was
found that for each medication introduced during hospita-
lization, there was a 10% increase in the rate of an overall
adverse event (po0.001), independent of other patient
characteristics. Similarly, the increase of one medication
during hospitalization caused a 14% increase in the chance of
HDR (po0.001). There was a 57% less chance of new ADRs in
patients with a previous history of ADRs (p=0.017) (Table 1).
The predictable ADRs, type A, were most frequently
observed (84% of ADRs), with gastrointestinal manifesta-
tions being the most common (Table 2). According to the
criteria developed by Naranjo et al., most of the ADRs were
classified as ‘‘possible or likely’’ because skin and/or pro-
vocation tests were not performed to confirm a causal rela-
tionship (16).
Symptomatic medications were the most commonly pre-
scribed. The primary medication groups that caused ADRs
were antibiotics (21.2%), followed by opioids (13.8%), and
iodinated contrast media (10.6%) (Figure 2). Seven patients
developed ADR due to drug interactions (Table 2). Skin
eruptions were the most common HDR (53.3%), followed by
hematologic (26.6%) and gastrointestinal manifestations
(13.3%); one patient had a systemic reaction (anaphylaxis).
There was no significant difference in the frequency of imme-
diate (i.e., occurring within 1 hour after the drug adminis-
tration) or non-immediate HDRs.
ADR incidence density varied between the medical
specialties. However, when considered collectively, we obser-
ved one patient with an ADR per 104 patients per day.
The probability of observing one HDR was one for every
500 patients in any one day (Table 3). According to the seve-
rity level described by Hartwig et al. (18), most ADRs were
moderate (44.7%), requiring treatment and/or extension of
hospital stay, followed by mild (42.5%), and severe (12.8%).
’ DISCUSSION
The prevalence of ADRs in this study as a cause of hospi-
talization was 1.7%, which is similar to another Brazilian
study, which observed an ADR prevalence of 2.1% in 10,272
patients (22). Higher rates, 3.3% in 4,332 patients and 6.5% in
18,820, have been shown in two European surveys. While the
objective of these studies were to assess the prevalence of
ADRs as the cause of hospital admission (6,23), we analyzed
hospitalized patients in specific clinical areas.
We observed an overall ADR incidence of 16.2%, with
variations in the different medical specialties that were
analyzed, and the incidence was higher in Internal Medicine
(30%). The overall incidence density observed showed the
likelihood of an ADR was one in every 104 patients hospi-
talized in any one day. Another study evaluated 3,695
patients and also found differences across 12 medical
specialties (1).
Several studies have shown similar values to ours, in terms
of general ADR incidence (between 10% and 15.8%) (1,4,
23-25), except for one study that observed a rate of 31% (7).
In terms of the Internal Medicine results, our incidence was
similar to the rate observed in another study, which found an
incidence of 22% (26). The discrepancy observed between
studies may be explained by differences in the study popu-
lations and the ADR definitions used.
There are limitations related to the Naranjo criteria, which
are intended to assess the likelihood of an ADR associated
with only one drug, and confounding variables can com-
promise the sensibility and specificity of this method, such as
other algorithms. However, these criteria are used by many
authors when reporting drug interactions and are recom-
mended by several journals to reviewers of manuscripts.
In a study comparing three different pharmacovigilance algo-
rithms (Kramer algorithm, Naranjo criteria and Jones algo-
rithm) used to assess the likelihood of an ADR in the intensive
Figure 1 - Incidence of ADRs and HDRs by medical specialty (%).
ADR: Adverse drug reaction HDR: Hypersensitivity drug reaction.
The ADR rate was higher in Internal Medicine (p=0.001).
Table 1 - Odds ratio of experiencing an ADR by medical specialty, history of previous ADR and number of medications.
Variable OR (95% CI) p
Medical Specialty OR (95% CI) in the Internal Medicine infirmary
Internal Medicine 1.00
Geriatrics 0.37 (0.18-0.78) 0.009
Neurology 0.25 (0.11-0.56) 0.001
General Surgery 0.17 (0.07-0.4) o0.001
Immunology 0.50 (0.019-1.34) 0.170
Previous ADR OR (95% CI) in relation to No Previous ADR
No 1.00
Yes 0.43 (0.23-0.8) 0.008
Number of medications
One mediation added 1.1 (1.06-1.13) o0.001
ADR: Adverse drug reaction.
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Table 2 - ADRs and related drugs.
ADR (n=94) Related drugs/number of reactions
Cardiovascular (4)
Acute atrial fibrillation Formoterol+Fenoterol (1)
Arterial hypertension Prednisone (1)
Postural hypotension Fentanyl (1) Hydrochlorothiazide (1)
Gastrointestinal (26)
Constipation Codeine (3) Tramadol (1)
Nausea and vomiting Potassium chloride (1) Mannitol (1) Iodinated contrast media (3) Dipyrone (1) Tramadol (1)
calcium gluconate (1) Morphine (1) Prednisone (1) Clindamycin (1) Calcium polystyrene sulfonate (1)
Epigastric pain Lactulose (1) Iron sulfate (1)
Diarrhea Bromopride (1) Iodinated contrast media (2) Omeprazole (1)
Abdominal cramps Vitamin B12 (1)
Hepatitis Ampicillin (1)*
Cholestasis Fluconazole (1)
Pancreatitis Furosemide (1)*
Infectious (3)
Pseudomembranous colitis Imipenem (1) Ciprofloxacin (1) Piperacillin/tazobactam (1)
Neurological (12)
Tremors Oxacillin (1)
Malaise, dizziness Metoclopramide (1)
Headache, dizziness and vomiting Carbamazepine (1)
Somnolence Haloperidol (1) Bromazepam (1)
Lowering NC, miosis Morphine (1)
Hallucinations and mental Confusion Escitalopram (1) Piperacillin/tazobactam (1) Codeine (2) Meropenem (1)
Convulsion Imipenem (1)
Kidney (17)
Renal failure Vancomycin (8) Captopril (1) Iodinated contrast media (1) Losartan (1) Amphotericin B (1) Furosemide (1)
Meloxicam (1)Mannitol+Bisacodyl+Lactulose (2) Ipratropium +Tiotropium (1)
Skin (10)
Erythroderma Vancomycin (1)*
Rash and itchy skin Cefazolin (1)*, Iodinated contrast media (1)*, Morphine (3)*
Maculopapular rash Ketoprofen (1)*
Itching Dipyrone (1) Gabapentin (1)
Angioedema + hives Ceftriaxone (1)*
Systemic (1)
Anaphylaxis Iodinated contrast media (1)*
Hematologic (9)
Hemolytic anemia Ceftriaxone (1)*
Pancytopenia Amphotericin B (1)*
Neutropenia Dipyrone (1)*
Leukopenia Cyclophosphamide+Vincristine (1)
Thrombocytopenia Unfractionated Heparin (1)*
Bleeding Warfarin (1) Clopidogrel+Acetilsalicilic acid+Enoxaparin (1) Acetilsalicilic acid+Enoxaparin (1)
Unfractionated Heparin (1)
Endocrine - Metabolic (10)
Hypotension and Hyponatremia Furosemide (1)
Hyperkalemia Enalapril (1) Losartan (1)
Hypokalemia Furosemide (1)
Edema Prednisone (1)
Hypoglycemia Glargine insulin (1)
Hyperglycemia Methylprednisolone (3) Prednisone (1)
Other (2)
Thoracic pain, nausea Iodinated contrast media (1)
*Hypersensitivity drug reaction.
Figure 2 - Most frequently prescribed medications (A) and medications associated with ADRs (B).
ADR: Adverse drug reactions.
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care unit showed similar results, suggesting that the selection of
any of these three instruments is reasonable (27).
Chronic renal failure patients had more ADRs, as did
patients with longer hospitalization stays, a greater number
of diagnoses, and greater number of medications used at
admission. The number of medications used was the only
independent risk factor for ADRs observed in this study,
which is similar to the results from another study (1). The
largest number of diagnoses during hospitalization was
observed in the Internal Medicine and Geriatric infirmaries,
reflecting the highest number of drugs prescribed in these
medical specialties, and the highest incidence of ADRs was
in Internal Medicine patients. Age was not an isolated risk
factor for ADRs, differing from other studies (7,23,26).
A history of previous ADR was a protective factor for the
occurrence of new ADRs (p=0.017), probably because the
awareness ’prevents’ further exposure to certain medication
classes. The only independent risk factor for HDR during
hospitalization was the number of medications on admis-
sion (po0.001), and each new medication prescribed for
patients during hospitalization, increased the rate of HDR
by 14%.
Type A reactions were the most common (84% of ADR),
particularly gastrointestinal manifestations, as in other stu-
dies (7,23-25,28-29). The incidence of skin reactions was
2%, which is higher than the rate of 0.7% reported in another
study (30). In HDRs, skin manifestations were the most
common presentations restricted to one organ (53.3%). Most
observed ADRs were classified as moderate, with high
morbidity, in accordance with other studies (26,29). The rate
of 12.8% for severe reactions observed in the present study is
also consistent with the literature (1,25,31).
Symptomatic medications were the most prescribed agents
during hospitalization, highlighted in descending order:
dipyrone, omeprazole and metoclopramide. Dipyrone use
is not permitted in many countries where paracetamol is
identified as the most prescribed alternative (23). Antibiotics
caused the most ADRs and HDRs (21.2%), followed by
opioids and iodinated contrast agents, which aligns with
current literature data (2,28).
ADRs are common and potentially serious events that
should be monitored through pharmacovigilance interven-
tions that increase the number of notifications because many
events are not reported spontaneously. Our study contributes
further evidence to warn health professionals about the
important role of rational use of medications and to support
the prevention of ADRs, a significant problem into health
systems, particularly in patients with chronic renal failure,
prolonged hospitalization, or those on ‘‘polypharmacy’’ medi-
cine regimens.
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